Biotech Values

[DewDiligence]

TSRO plans phase-1/2 trial of ALK-inhibitor, TSR-011, in NSCLC and other cancers:

http://finance.yahoo.com/news/tesaro-announces-clearance-investigational-drug-203000058.html

Following identification of the maximum tolerated dose of TSR-011 in the dose escalation phase of the Phase 1/2 study, TESARO plans to evaluate TSR-011 in three parallel cohorts of patients: those with ALK+ non-small cell lung cancer (NSCLC) who have not been previously treated with ALK inhibitors, those with NSCLC who have progressed during treatment with other ALK inhibitors and those with other tumor types expressing ALK.

TSRO has risen about 15% since its Jun 2012 IPO @$13.50 (#msg-77039735).